Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 31, 2024 12:43pm

76 Views

Post# 36066525

RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

Pfizer's enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate currently used for the treatment of urothelial cancer in combination with the checkpoint inhibitor pembrolizumab ( Keytruda).

The antibody-drug conjugate (ADC) Padcev does not have a chemotherapy payload which consequently sets up this category of ADCs for the addition of ONCY's pelareorep in combination with a PD-L1 immune checkpoint inhibitor, such as keytruda or tecentriq, for example.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects